Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Journal for Immunotherapy of Cancer|April 9, 2026
HosTIL territory: mapping the landscape of toxicity in TIL therapyRachel Woodford, Maria Jose Demiguelarroyo, Ragini Jethra, et al.
Systematic Reviews|September 30, 2023
Patient-reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic reviewSally Taylor, Kate Law, Jake Coomber-Moore, et al.
The Lancet Regional Health. Europe|May 8, 2026
Advances in cell therapy for solid tumours: European perspective and future directionsVictor Moreno, Fiona Thistlethwaite, Ramón Yarza, et al.
Ejhaem|August 21, 2023
Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignanciesKyrillus S Shohdy, Manon Pillai, Ryan Guest, et al.
Psycho-Oncology|April 6, 2026
Psychological Screening and Support for Patients Enrolled in Early-Phase Cancer Clinical Trials and the Possible Barriers: A Real-World Tertiary Center Implementation StudyMatthew D Robinson, Ruiyang Yan, Amy Smith, et al.
BMC Cancer|April 19, 2024
Development and validation of a patient reported experience measure for experimental cancer medicines (PREM-ECM) and their carers (PREM-ECM-Carer)Chelsea S Sawyer, Sally Taylor, Louise Carter, et al.
NPJ Precision Oncology|March 26, 2025
Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patientsJulio Herrero Colomina, Eleanor Johnston, Kate Duffus, et al.
Journal of Biomedical Informatics|April 27, 2023
Meta-analysis informed machine learning: Supporting cytokine storm detection during CAR-T cell TherapyAlex Bogatu, Magdalena Wysocka, Oskar Wysocki, et al.
BMJ Open|March 20, 2024
Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representativesRobin Chatters, Munyaradzi Dimairo, Cindy Cooper, et al.
Eclinicalmedicine|January 15, 2026
Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation studyWynne Wijaya, Thomas Morris, Martin D Forster, et al.
Pageof 5